Keckley Report November 23, 2020
Last week, Moderna joined Pfizer in announcing promising results of their messenger RNA vaccines and their intent to file for emergency use authorization with the FDA within days. A third vaccine by Astra Zeneca-Oxford University, significant because it is a viral vector vaccine, is not far behind. And Saturday, a second drug by Regeneron received FDA emergency use approval on the heels of Eli Lilly’s approval earlier this month. That’s encouraging.
Arguably, Operation Warp Speed is a resounding success: the investment of $10.75 billion in vaccine development (Pfizer- BioNTech $1.95 billion, Moderna $2.5 billion, J&J $1.5 billion, Astra Zeneca $1.2 billion, Sanofi with GSK $2 billion, and Novavax $1.6 billion) brings hope for a return to normalcy next year. But...